Serplulimab Achieves 42.5% pCR Rate in Neoadjuvant Colon Cancer
The 2026 European Society for Radiotherapy and Oncology (ESTRO 2026) was held in Stockholm, Sweden, from May 15 to 19 local time. At this conference, Henlius’ innovative anti-PD-1 monoclonal antibody(mAb) serplulimab was officially presented in an oral report for its neoadjuvant therapy study results in locally advanced high-risk colon cancer (LACC). The study was jointly initiated by Professor Sanjun Cai and Professor Zhen Zhang of Fudan University Shanghai Cancer Center. The results showed that radiochemotherapy combined with serplulimab demonstrated favorable efficacy, with the pathological complete response (pCR) rate significantly increased to 42.5%, representing more than a four-fold improvement over the control group. This offers a new treatment option for high-risk LACC and further validates the therapeutic value of serplulimab in the field of gastrointestinal cancers.
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data